• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
ZHANG Nannan,LI Jing,YANG Shu,CAO Zhongshu.The effects of ibandronate on OST and BAP in hepatic carcinoma with bone metastases patients[J].Journal Of Pharmaceutical Research,2016,35(7):422-424[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 3534times   Download 2844次 QR Code for this article
Scan with your phone!
伊班膦酸钠对肝癌并骨转移骨钙素及骨碱性磷酸酶的影响
张囡囡,李静,杨舒,曹忠书
Font:Larger+|Default|Smaller-
(山东省枣庄矿业集团中心医院,山东 枣庄 277800)
摘要:
目的 探讨骨钙素(osteocalcin,OST)、骨碱性磷酸酶(bone alkaline phosphatase,BAP)对肝癌并骨转移的预测作用及其伊班磷酸钠对骨代谢的影响。方法 收集肝癌并骨转移患者16例、肝癌并非骨转移患者22例及肝癌无转移患者20例,并予伊班磷酸钠治疗肝癌并骨转移组,检测各组及肝癌并骨转移治疗前、治疗28、56及84 d骨钙素、骨碱性磷酸酶水平,比较各组间及治疗前后其差异。结果 肝癌并骨转移组、肝癌非骨转移组、无转移组血清骨钙素水平分别为31.12±4.18、13.00±6.92、10.23±1.34,骨碱性磷酸酶分别为20.11±1.65、11.41±1.25、10.78±1.35,其中骨转移组骨钙素及骨碱性磷酸酶水平较其他两组差异有统计学意义(P<0.05)。伊班膦酸钠注射液可降低肝癌骨转移组骨钙素及骨碱性磷酸酶水平,治疗后较治疗前差异有统计学意义(P<0.05)。结论 骨钙素、骨碱性磷酸酶对肝癌并骨转移患者有较好的预测作用,伊班膦酸钠注射液有效治疗骨转移瘤,机制可能与降低骨钙素及骨碱性磷酸酶相关。
关键词:  肝癌  骨转移  骨钙素  骨碱性磷酸酶  伊班膦酸钠
DOI:10.13506/j.cnki.jpr.2016.07.016
基金项目:
The effects of ibandronate on OST and BAP in hepatic carcinoma with bone metastases patients
ZHANG Nannan,LI Jing,YANG Shu,CAO Zhongshu
(Central Hospital of Zaozhuang Mining Group,Zaozhuang 277800,China)
Abstract:
Objective To investigate the prognosis of OST(osteocalcin) and BAP(bone alkaline phosphatase)for hepatic carcinoma with bone metastases patients and valuation of Ibandronate.Methods 16 patients of hepatic carcinoma with bone metastases,22 patients of hepatic carcinoma without bone metastases and 20 patients of hepatic carcinoma without metastases were collected.The hepatic carcinoma with bone metastases group was treated with Ibandronate.To observe the defferences of the BAP and OST in three groups and treatment or not.Results The levels of OST and BAP increased significantly in the bone metastasis group(P<0.05).Ibandronate Injection reduced the levels of OST and BAP in hepatic carcinoma with bone metastasis group. Conclusion The value of BAP and OST were significantly higher in hepatic carcinoma with bone metastases patients,which can be used as reference index of clinical prediction.Ibandronate Injection was effective in the treatment of bone metastases and the mechanism may be related to reduce the levers of OST and BAP.
Key words:  Hepatic carcinoma  Bone metastasis  Osteocalcin  Bone-specific alkaline phosphatase  Ibandronate
Today's Visits:487    Total Visits:2383201
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.